| Project/Area Number |
18591492
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Tazuke Kofukai Medical Research Institute |
|---|
Principal Investigator |
UEDA Shugo Tazuke Kofukai Medical Research Institute, 2nd Division, Medical Research Institute, Researcher (80372580)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NAKAMURA Hajime Kyoto University, Graduate School of Medicine, Associate Professor (70303914)
YODOI Junji Kyoto University, Institute for Virus Research, Professor (80108993)
|
|---|
| Project Period (FY) |
2006 – 2007
|
| Project Status |
Completed (Fiscal Year 2007)
|
| Budget Amount *help |
¥3,890,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥390,000)
Fiscal Year 2007: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2006: ¥2,200,000 (Direct Cost: ¥2,200,000)
|
|---|
| Keywords | anticancer drug / chemosensitivity / predictive marker / galectin-7 / thioredoxin / adverse event / stress / cisplatin / 進行胃癌 / 感受性マーカー / 肺癌 / 間質性肺炎 |
|---|
| Research Abstract |
Chemotherapeutic agents have an important role in treatment for advanced cancer, and it is necessary to develop predictive markers for the drug response. The purpose of this research was to identify the predictive markers among stress-inducible genes that regulate apoptosis signal using clinical cancer samples.
We showed that neoadjuvant chemotherapy with S-1 and cisplatin was effective for advanced gastric cancer patients. Although we examined the gene expression in the cancer samples collected endoscopically before chemotherapy, we could not specify genes that predict the chemo-sensitivity. We demonstrated that stress-inducible galectin-7 gene was highly expressed in cisplatin-sensitive urinary bladder cancer, and that galectin-7 augmented the cisplatin-induced apoptosis by generation of reactive oxygen species (ROS) and activation of c-Jun N-terminal kinase (JNK).
We measured plasma thioredoxin levels in non-small-cell lung cancer patients to identify predictive marker for adverse events during chemotherapy. We showed the plasma thioredoxin levels were high in patients with interstitial lung disease, severe adverse event associated with treatment with epidermal growth factor receptor (EGFR) inhibitor, gefitinib.
Our results suggest the future possibility of developing novel tailored therapeutic strategy for cancer by monitoring redox-regulating molecule and stress-inducible gene expression.
|
